Introduction
============

Infantile hemangiomas are benign tumors of vascular origin that affect approximately 10% of the pediatric population. These tumors are characterized by a rapid proliferation phase over the first 1--2 years of the child's life, followed by a slow and steady decline over the next 5--7 years leading to the complete involution of the tumor mass. Approximately 90% of all infantile hemangiomas remain small and are best left alone to naturally involute. However in about 10% of the cases the tumors exhibit aggressive characteristics based on their size, location, number, etc. and must be actively treated to avoid patient disfigurement and/or mortality.

The etiology of infantile hemangiomas is largely unknown, particularly with regard to the cellular origin of the tumor. Circumstantial evidence suggests that these lesions are of aberrant placental origin as evidenced by upregulated Glut1 expression \[[@B1]\], and some labs have ventured to hypothesize that they may be formed from metastatic invasion of placenta-derived chorangioma cells \[[@B2]\]. Indeed, transcriptional profiling of human placenta, infantile hemangioma, and eight normal and diseased vascularized tissues suggests that high transcriptome similarity is shared between placenta and hemangioma tissues, more so than any of the other tissues tested \[[@B3]\]. Global gene expression analysis of infantile hemangioma tumors has been previously performed by two labs. Ritter et al. \[[@B4]\] utilized microarray analysis on whole tumors and identified immune regulators and indoleamine 2,3 dioxygenase as key regulators of infantile hemangioma involution. Calicchio et al. \[[@B5]\] utilized laser capture microdissection and genome-wide transcriptional profiling of vessels from proliferating and involuting hemangiomas. The authors strongly associated proliferating hemangioma vessels with increased expression of genes involved in endothelial-pericyte interactions and neuronal/vascular patterning, and involuting hemangiomas with chronic inflammatory mediators and angiogenic inhibitors. Given the high density of tightly associated pericytes in infantile hemangiomas and the inevitable collateral capture of intraluminal white cells, fibroblasts, mast cells, and perivascular collagen with laser microdissection, these data represent changes from numerous cell types within the infantile hemangioma tumor, but are not reflective specifically of the aberrant endothelial cells which contribute to disease. While these genomics studies have provided great mechanistic insight into the etiology and progression of the disease, they have not addressed the unique differences between abnormal infantile hemangioma endothelial cells and the normal dermal endothelial cells that are resident in the surrounding skin area of the patient. Understanding these differences could identify targetable pathways that could be exploited to preferentially block hemangioma growth and spread, but spare normal endothelial cells.

To date, no direct whole genome comparison of pure cultures of human dermal microvascular endothelial cells (HDMVECs) and infantile hemangioma endothelial cells (HEMECs) has been reported. To address this, we performed whole genome microarray profiling of the gene expression alterations between low passage pure cultures of HEMECs and HDMVECs. We identified a number of transcriptional alterations that are likely to contribute to the aggressive phenotype of infantile hemangiomas and that could potentially be utilized in immunotherapy against particularly aggressive hemangiomas tumors.

Materials and methods
=====================

Cell culture and chemicals
--------------------------

The HEMEC cell line was previously isolated from a proliferating-phase infantile hemangioma specimen collected from a female infant and generously donated to us by Joyce Bischoff (Harvard Medical School) \[[@B6]\]. The primary culture of neonatal HDMVECs was purchased from ATCC. Both cell lines were cultured as previously reported \[[@B7]\]. For all experiments, cell lines were used at \<5 passages.

Proliferation assay
-------------------

Cells were plated at equivalent sub-confluent densities and maintained in a Nikon Biostation CT time lapse imaging station. Cell proliferation was measured by counting cells per vision field from 5 independent areas over a 96 hour time course. Data presented is the average of the counts plus or minus the standard deviation. Student's *t*-test was used to evaluate statistical significance. Data with p\<0.05 was considered significant.

Migration assay
---------------

Confluent cultures were scratch wounded and the progress of "wound healing" was monitored using a Nikon Biostation CT time lapse imaging station over a 9 hour period. Data presented is the average migration speed plus or minus the standard deviation. Student's *t*-test was used to evaluate statistical significance (p\<0.05). Data with p\<0.05 was considered significant.

Immunofluorescence
------------------

Cells were plated onto collagen type I coated glass coverslips, fixed in 4% paraformaldehyde, and incubated with antibodies against phospho-focal adhesion kinase (p-FAK; 1:1000; Cell Signaling \#3283), rhodamine conjugated phalloidin (1:350; Cytoskeleton Inc.), or DAPI and imaged via a Nikon Eclipse Ti laser scanning confocal microscope.

Microarray analysis
-------------------

Total RNA was amplified and biotin-labeled using Illumina TotalPrep RNA Amplification Kit (Ambion). 750 ng of biotinylated aRNA was then briefly heat-denatured and loaded onto expression arrays to hybridize overnight. Following hybridization, arrays were labeled with Cy3-streptavidin and imaged on the Illumina ISCAN. Intensity values were transferred to Agilent GeneSpring GX microarray analysis software and data was filtered based on quality of each call. Statistical relevance was determined using ANOVA with a Benjamini Hochberg FDR multiple testing correction (p-value \< 0.05). Data were then limited by fold change analysis to statistically relevant data points demonstrating a 2-fold or more change in expression. Pathway analysis was performed using Metacore software. The microarray data from this experiment is publically available on the Gene Expression Omnibus (GEO Accession \#GSE43742).

Quantitative real time PCR analysis
-----------------------------------

RNA was isolated from cells using the Ambion Purelink Minikit according to the manufacturer's directions. qRT-PCR was performed on an ABI7900HT RT-PCR system using TaqMan Assays with predesigned primer sets for the genes of interest (Invitrogen). All RT-PCR experiments were performed in triplicate.

Immunohistochemistry
--------------------

Paraffinized infantile hemangioma tissues were labeled with CTAG2 antibody (1:200, Santa Cruz Biotechnology \#sc99243) and quantified using Alkaline Phosphatase detection (CellMarque). Positive and negative controls from breast carcinoma tissues were stained with CTAG2 antibody or sham, respectively. Use of de-identified human tissues was approved by the Texas Tech University Health Sciences Center Institutional Review Board for the Protection of Human Subjects (IRB E13029). Waiver of informed consent was approved by IRB.

Results and discussion
======================

A comparison of the proliferation and migration rates of HEMECs and HDMVECs under standard growth conditions revealed no significant difference between normal and hemangioma endothelial cell types, however HEMECs grown under reduced serum conditions (0.5% fetal bovine serum) exhibited an approximately 30% increase in proliferation and an approximately 18% increase in migration relative to HDMVECs grown under the same conditions (Figure [1](#F1){ref-type="fig"}A & B). This suggests the higher serum concentrations were likely masking any phenotypic advantage attributed to the HEMECs. Moreover, it indicates the proliferative and migratory capacity of HEMECs are unique from that observed in HDMVECs and agrees with earlier reports suggesting advantages in these areas for HEMECs \[[@B6]\]. Comparisons of fluorescent images of the actin cytoskeleton and active focal adhesion complexes obtained with confocal microscopy revealed that HDMVECs display primarily peripheral membrane localized p-FAK, indicating sites of cellular attachment to the extracellular matrix (ECM) (Figure [1](#F1){ref-type="fig"}C). In contrast, p-FAK localization in HEMECs was observed along the entirety of the actin stress fibers, suggesting cellular adhesion to its substrate is markedly altered in HEMECs. Indeed, it has previously been reported that HEMECs display unique expression of genes involved in cellular adhesion \[[@B8]\].

![**Analysis of HDMVEC and HEMEC phenotypes.** (**A**) Analysis of proliferation rates between HDMVECs and HEMECs over a 48 hr time course. (**B**) Analysis of the migration rates of HDMVECs and HEMECs nine hours after initial scratch from a micropipette. (**C**) Immunofluorescent imaging of actin (*red*), p-FAK (*green*), and nucleus (*blue*). (red asterisks for panels **A** &**B** represent statistically significant values \[p\<0.05\] as determined by Student's *t*-test).](2045-824X-5-6-1){#F1}

Whole genome microarray analysis reveals large scale alterations in gene expression between HEMECs and HDMVECs
--------------------------------------------------------------------------------------------------------------

Given the phenotypic differences observed between HEMECs and HDMVECs, we compared the global gene expression patterns between pure cultures of these cells using Illumina high density BeadArrays to elucidate which molecular factors are deregulated in HEMECs. Our array analysis identified 125 genes whose expression was upregulated and 104 genes whose expression was downregulated (2 fold or greater, p\<0.05) in HEMECs compared to HDMVECs (Table [1](#T1){ref-type="table"}). Metacore analysis of the 2 fold or greater gene expression changes revealed three major classifications of gene functions that are altered in HEMECs including cell adhesion (*TIMP1, COL1A1, COL1A2, MMP1, MMP13, SERPINE2, COL4A6, LAMC2, MMP2, CD44, CAV1, CCL2, JAM3, CLDN11, LYVE1*), cell cycle (*CCND2, CDKN2A, CCNA1, NCAPD2*), and arachidonic acid production (*ACSL5, FAP, LIPG, PLA2G4C*). Given the number of adhesion genes whose expression is altered in HEMECs compared to HDMVECs, it is no surprise that we observed altered subcellular localization of p-FAK in HEMECs (Figure [1](#F1){ref-type="fig"}C), reflecting a unique adhesive phenotype in these cells. Our data reflect altered cell cycle regulation in HEMECs, with a downregulation of *CCND2 (*cyclin D2) and CDKN2A (p16Ink4A) and a potent 6.6 fold increase in *CCNA1* (cyclin A1), and these changes may contribute to the enhanced proliferation rates in HEMECs and the uncontrolled cell growth observed in infantile hemangiomas tumors. Alterations in the expression of genes involved in arachidonic acid production were unique in that this polyunsaturated fatty acid can serve as a lipid second messenger in the regulation of phospholipase-C and protein kinase-C signaling, is a key inflammatory intermediate, and can act as a vasodilator \[[@B9]\].

###### 

Fold changes in mRNA expression levels of genes in HEMECs compared to HDMVECs

  **Gene symbol**                            **Gene name**                           **Accession number**   **FC**
  ----------------- --------------------------------------------------------------- ---------------------- --------
  CTAG2                                 Cancer/testis antigen 2                          NM_020994.3         11.6
  IL13RA2                          Interleukin 13 Receptor, alpha 2                      NM_000640.2         10.7
  IFI27                         Interferon, alpha-inducible protein 27                   NM_005532.3         8.3
  TPM2                                   Tropomyosin 2 (beta)                            NM_213674.1         7.8
  RPL14                                  Ribosomal protein L14                          NM_001034996.1       6.6
  CCNA1                                        Cyclin A1                                 NM_003914.3         6.6
  RGS5                              G-protein signaling 5 regulator                      NM_003617.3         6.0
  FBN2                                        Fibrillin 2                                NM_001999.3         5.9
  D4S234E                        DNA segment on chromosome 4 (unique)                   NM_001040101.1       5.5
  BST2                            Bone marrow stromal cell antigen 2                     NM_004335.2         5.1
  QPCT                            Glutaminyl-peptide cyclotransferase                    NM_012413.3         4.8
  TNFSF4                 Tumor necrosis factor (ligand) superfamily, member 4            NM_003326.3         4.6
  RGS5                            Regulator of G-protein signaling 5                     NM_003617.3         4.6
  SPOCK1             Sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1       NM_004598.3         4.6
  SNHG8                  Small nucleolar RNA host gene 8 (non-protein coding)            NR_003584.3         4.6
  ANTXR1                               Anthrax toxin receptor 1                          NM_032208.2         4.5
  CHST1                             Carbohydrate sulfotransferase 1                      NM_003654.5         4.5
  MPZL2                               Myelin protein zero-like 2                         NM_005797.3         4.4
  HEY2                     Hairy/enhancer-of-spilt related with YRPW motif 2             NM_012259.2         4.3
  SLITRK4                         SLIT and NTRK-like family, member 4                    NM_173078.3         4.2
  SHISA2                                    Shisa homolog 2                             NM_001007538.1       4.0
  LRRC17                        Leucine rich repeat containing 17, TV2                   NM_005824.2         3.9
  NUDT11                                  Nudix-type motif 11                            NM_018159.3         3.8
  RNASE1                         Ribonuclease, Rnase A family, 1, TV1                    NM_198235.2         3.7
  SERPINE2                   Serpin peptidase inhibitor, clade E, member 2               NM_006216.3         3.6
  LIPG                                    Lipase, endothelial                            NM_006033.2         3.4
  PCSK5                      Proprotein convertase subtilisin/kexin type 5               NM_006200.3         3.4
  LPXN                                         Leupaxin                                  NM_004811.2         3.3
  CXCR4                         Chmeokine (C-X-C motif) receptor 4, TV2                  NM_003467.2         3.2
  TMEM200A                            Transmembrane protein 200A                         NM_052913.2         3.1
  CXCR4                         Chemokine (C-X-C motif) receptor 4, TV1                 NM_001008540.1       3.1
  RAB34                            RAB34, member RAS onogene family                      NM_031934.5         3.0
  DPYSL3                              Dihydropyrimidinase-like 3                         NM_001387.2         2.9
  FBXL13                       F-box and leucine-rich repeat protein 13                  NM_145032.3         2.9
  PNMA2                               Paraneoplastic Ma antigen 2                        NM_007257.5         2.9
  LOC440354                                    LOC440354                                 NR_002473.2         2.9
  NLGN1                                      Neuroligin 1                                NM_014932.2         2.8
  DDIT4                            DNA-damage-inducible transcript 4                     NM_019058.2         2.8
  PFN2                                        Profilin 2                                 NM_053024.3         2.8
  GABBR2                         Gamma-aminobutyric acid B receptor, 2                   NM_005458.7         2.8
  MEIS2                                     Meis homeobox 2                              NM_172315.2         2.7
  PMEPA1                  Prostate transmembrane protein, androgen induced 1             NM_199169.2         2.7
  LOC647307                                    LOC647308                                 XR_039752.1         2.7
  PLEK2                                      Pleckstrin 2                                NM_016445.1         2.7
  CARD11                     Caspase recruitment domain family, member 11                NM_032415.4         2.6
  SNORD13                Small nucleolar RNA, C/D box 13, small nucleolar RNA            NR_003041.1         2.6
  GFPT2                      Glutamine-fructoce-6-phosphate transaminase 2               NM_005110.2         2.6
  FAP                            Fibroblast activation protein, alpha                    NM_004460.2         2.6
  OCIAD2                             OCIA domain containing 2, TV2                       NM_152398.2         2.5
  F2RL1                          Coagulation factor II receptor-like 1                   NM_005242.4         2.5
  DSTYK                    Dual serine/threonine and tyrosine protein kinase             NM_199462.2         2.5
  LOC649497                                    LOC649498                                 XM_938576.1         2.5
  LOC654194                                    LOC654195                                 XM_942669.1         2.5
  NYNRIN                    NYN domain and retroviral integrase containing               NM_025081.2         2.5
  LOC387763                                    LOC387764                                 XM_941665.2         2.5
  COL8A1                             Collagen, type VIII, alpha 1                        NM_020351.3         2.5
  MGC39900                                     MGC39901                                  XM_936687.1         2.4
  LTBP2                Latent transforming growth factor beta binding protein 2          NM_000428.2         2.4
  RNASE1                         Ribonuclease, Rnase A family, 1, TV3                    NM_198232.2         2.4
  IFI27L2                    Interferon, alpha-inducible protein 27-like 2               NM_032036.2         2.4
  SOX4                            SRY (sex determining region Y)-box4                    NM_003107.2         2.4
  LRRC17                        Leucine rich repeat containing 17, TV1                  NM_001031692.2       2.3
  DSE                                 Dermatan sulfate epimerase                         NM_013352.2         2.3
  CD44                          CD44 molecule (Indian blood group), TV5                 NM_001001392.1       2.3
  LOC100131139                               LOC100131140                                XR_037336.1         2.3
  CBS                                 Systathionine-beta-synthase                        NM_000071.2         2.3
  NT5DC2                         5\'-nucleotidase domain containing 2                    NM_022908.2         2.3
  NPFFR2                              Neuropeptide FF receptor 2                         NM_004885.2         2.3
  LOC100129685                               LOC100129686                               XM_001723814.1       2.3
  LXN                                           Latexin                                  NM_020169.3         2.3
  MEX3B                                     Mex-3 homolog B                              NM_032246.3         2.3
  C1orf54                         Chromosome 1 open reading frame 54                     NM_024579.3         2.3
  HDDC2                                 HD domain containing 2                           NM_016063.2         2.3
  LOC648823                                    LOC648824                                 XM_943477.1         2.3
  CYB5A                                  Cytochrome b5 type A                            NM_001914.3         2.3
  PIR                            Pirin (iron binding nuclear protein)                   NM_001018109.2       2.3
  GPR37                              G protein-coupled receptor 37                       NM_005302.2         2.3
  PPAPDC1A             Phosphatidic acid phosphatase type 2 domain containing 1A        NM_001030059.1       2.3
  CD44                          CD44 molecule (Indian blood group), TV4                 NM_001001391.1       2.2
  LOC100131905                               LOC100131906                                XR_039334.1         2.2
  CTAG1A                               Cancer/testis antigen 1A                          NM_139250.1         2.2
  C4orf18                         Chromosome 4 open reading frame 18                     NM_016613.6         2.2
  LDOC1                       Leucine zipper, down-regulated in cancer 1                 NM_012317.2         2.2
  TGFBI                        Transforming growth factor, beta-induced                  NM_000358.2         2.2
  COL5A2                               Collagen, type V, alpha 2                         NM_000393.3         2.2
  NOX4                                      NADPH oxidase 4                              NM_016931.3         2.2
  TSHZ3                             Teashirt zinc finger homeobox 3                      NM_020856.2         2.2
  FNDC3B                    Fibronectin type III domain containing 3B, TV2              NM_001135095.1       2.2
  KIT                                            V-kit                                  NM_001093772.1       2.2
  ADAM19                            ADAM metallopeptidase domain 19                      NM_033274.3         2.2
  JAM3                              Junctional adhesion molecule 3                       NM_032801.4         2.1
  CGNL1                                     Cingulin-like 1                              NM_032866.4         2.1
  COL4A6                              Collagen, type IV, alpha 6                         NM_001847.2         2.1
  BMX                              BMX non-receptor tyrosine kinase                      NM_001721.6         2.1
  DUSP23                            Dual specificity phosphatase 23                      NM_017823.3         2.1
  MMP2                                 Matrix metallopeptidase 2                         NM_004530.4         2.1
  NCAPD2                        Non-SMC condensin I complex, subunit D2                  NM_014865.3         2.1
  CYBRD1                             Cytochrome b reductase 1, TV1                       NM_024843.2         2.1
  FAM89A                     Family with sequence similarity 89, member A                NM_198552.2         2.1
  GAS6                                 Growth arrest-specific 6                          NM_000820.2         2.1
  S100A13                          S100 calcium binding protein A13                     NM_001024211.1       2.1
  SMARCE1                       SWI/SNF related, subfamily e, member 1                   NM_003079.4         2.1
  LOC643977                                    LOC643978                                 XM_932991.1         2.1
  LFNG                  O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase         NM_001040167.1       2.1
  MTMR11                            Myotubularin related protein 11                      NM_181873.3         2.1
  ITGA10                                  Integrin, alpha 10                             NM_003637.3         2.1
  PTGFRN                     Prostaglandin F2 receptor negative regulator                NM_020440.2         2.0
  LOC644936                             Actin, beta pseudogene                           NR_004845.1         2.0
  CPS1                       Carbamoyl-phosphate synthase 1, mitochonfrial               NM_001875.4         2.0
  C18orf56                        Chromosome 18 open reading frame 56                   NM_001012716.2       2.0
  ADA                                     Adenosine deaminase                            NM_000022.2         2.0
  NETO2                              Neuropilin and tolliod-like2                        NM_018092.4         2.0
  DKFZp761P0423                              DKFZp761P0424                               XM_291277.4         2.0
  STC2                                      Stanniocalcin 2                              NM_003714.2         2.0
  PRKAR1A              Protein kinase, cAMP-dependent, regulatory, type I, alpha         NM_002734.3         2.0
  EGFLAM                 EGF-like, fibronectin type III and laminin G domains            NM_182801.2         2.0
  SPECC1              Sperm antigen with calponin homology, coiled-coil domains 1       NM_001033555.2       2.0
  FNDC3B                    Fibronectin type III domain containing 3B, TV1               NM_022763.3         2.0
  THOC3                                      THO complex 3                               NM_032361.2         2.0
  COL5A1                               Collagen, type V, alpha 1                         NM_000093.3         2.0
  LANCL1                    LanC lantibiotic synthetase component C-like 1               NM_006055.2         2.0
  OCIAD2                             OCIA domain containing 2, TV1                      NM_001014446.1       2.0
  LRIG1                 Leucine-rich repeats and immunoglobulin-like domains 1           NM_015541.2         2.0
  HOXB2                                       Homeobox B2                                NM_002145.3         2.0
  TIMP1                            TIMP metallopeptidase inhibitor 1                     NM_003254.2         −2.0
  NAAA                              N-acylethanolamine acid amidase                      NM_014435.3         −2.0
  MAOA                                    Monoamine oxidase A                            NM_000240.2         −2.0
  MYOF                                         Myoferlin                                 NM_013451.3         −2.0
  KISS1                               KiSS metastasis-suppressor                         NM_002256.3         −2.0
  SLC25A22                        Solute carrier family 25, member 22                    NM_024698.5         −2.0
  NOSIP                        Nitric oxide synthase interacting protein                 NM_015953.3         −2.0
  COL1A2                               Collagen, type I, alpha 2                         NM_000089.3         −2.0
  ZDHHC14                        Zinc finger, DHHC-type containing 14                    NM_024630.2         −2.0
  HPCAL1                                  Hippocalcin-like 1                             NM_134421.1         −2.0
  VLDLR                          Very low density lipoprotein receptor                  NM_001018056.1       −2.0
  LOC730525                                    LOC730525                                XM_001126202.1       −2.0
  BMP2                               Bone morphogenetic protein 2                        NM_001200.2         −2.0
  ABLIM1                              Actin binding LIM protein 1                        NM_006720.3         −2.0
  PIK3C2A                Phosphoinositide-3-kinase, class 2, alpha polypeptide           NM_002645.2         −2.0
  IRF1                              Interferon regulatory factor 1                       NM_002198.2         −2.0
  MBP                                    Myelin basic protein                           NM_001025100.1       −2.0
  PRKAR1B               Protein kinase, cAMP-dependent, regulatory type I, beta          NM_002735.2         −2.1
  FAM101B                    Family with sequence similarity 101, member B               NM_182705.2         −2.1
  ERCC2                              DNA excision repair protein 2                       NM_000400.3         −2.1
  CCND2                                        Cyclin D2                                 NM_001759.3         −2.1
  HLA-B                      Major histocompatibility complex, class I, B                NM_005514.6         −2.1
  SYBU                                        Syntabulin                                NM_001099743.1       −2.1
  PDE2A                          Phosphodiesterase 2A, cGMP-stimulated                   NM_002599.4         −2.1
  AKAP12                              A kinase anchor protein 12                         NM_005100.3         −2.1
  CLEC2B                        C-type lectin domain family 2, member B                  NM_005127.2         −2.1
  S100A4                            S100 calcuim binding protein A4                      NM_019554.2         −2.1
  FST                                         Follistain                                 NM_013409.2         −2.2
  SLC30A3                         Solute carrier family 30, member 3                     NM_003459.4         −2.2
  PLIN2                                       Perilipin 2                                NM_001122.3         −2.2
  IL32                                      Interleukin 32                              NM_001012633.1       −2.2
  LOC100128252                               LOC100128253                               XM_001725603.1       −2.2
  TIMM22                Translocase of inner mitochondrial membrane 22 homolog           NM_013337.2         −2.2
  SYNM                          Synemin, intermediate filament protein                   NM_015286.5         −2.2
  LOC729985                                    LOC729986                                XM_001131964.1       −2.2
  ADRB2                          Adrenergic, beta-2-, receptor surface                   NM_000024.5         −2.2
  KIAA1274                                     KIAA1274                                  NM_014431.2         −2.2
  PRR5                                      Proline rich 5                              NM_001017529.2       −2.2
  LOC387841                                    LOC387842                                 XM_932678.1         −2.3
  CFI                                     Complement factor I                            NM_000204.3         −2.3
  LOC646836                                    LOC646837                                XM_001718162.1       −2.3
  COL1A1                               Collagen, type I, alpha 1                         NM_000088.3         −2.3
  CCL2                              Chemokine (C-C motif) ligand 2                       NM_002982.3         −2.3
  COL6A1                              Collagen, type VI, alpha 1                         NM_001848.2         −2.3
  LOC201651                                    LOC201652                                 XR_017321.2         −2.3
  GALNTL4                               GalNAc-T-like protein 4                          NM_198516.2         −2.3
  S100A3                            S100 calcuim binding protein A3                      NM_002960.1         −2.4
  ALDH1A1                     Aldehyde dehydrogenase 1 family, member A1                 NM_000689.4         −2.4
  TNFRSF14               Tumor necosis factor receptor superfamily, member 14            NM_003820.2         −2.4
  CAV1                                        Caveolin 1                                 NM_001753.4         −2.4
  LAMC2                                    Laminin, gamma 2                              NM_005562.2         −2.4
  NOSTRIN                          Nitric oxide synthase trafficker                      NM_052946.3         −2.4
  CEACAM1              Carcinoembryonic antigen-related cell adhesion molecule 1        NM_001024912.2       −2.4
  CYYR1                                Cysteine/tyrosine-rich 1                          NM_052954.2         −2.5
  SLC22A23                        Solute carrier family 22, member 23                    NM_021945.5         −2.5
  ACSL5                     Acyl-CoA synthetase long-chain family member 5               NM_016234.3         −2.5
  AADAC                                Arylacetamide deacetylase                         NM_001086.2         −2.6
  COLEC12                           Collectin sub-family member 12                       NM_130386.2         −2.6
  KIAA1324L                                  KIAA1324-like                               NM_152748.3         −2.6
  RNASET2                                   Ribonuclease T2                              NM_003730.4         −2.6
  NXN                                        Nucleoredoxin                               NM_022463.4         −2.6
  PLA2G4C                             Phospholipase A2, group IVC                        NM_003706.2         −2.6
  SERPINB2                   Serpin peptidase inhibitor, clade B, member 2               NM_002575.2         −2.6
  CETP                        Cholesteryl ester transfer protein, plasma                 NM_000078.2         −2.7
  PLA2G16                             Phospholipase A2, group XVI                        NM_007069.3         −2.7
  TNFSF18                    Tumor necrosis factor superfamily, member 18                NM_005092.3         −2.8
  CITED2                         Cbp/p300-interacting transactivator 2                   NM_006079.3         −2.8
  C10orf116                       Chromosome 10 open reading fame 116                    NM_006829.2         −2.8
  PROX1                                   Prospero homeobox 1                            NM_002763.3         −2.9
  PALM                                        Paralemmin                                 NM_002579.2         −2.9
  ZSCAN18                      Zinc finger and SCAN domain containing 18                 NM_023926.4         −2.9
  LEPREL1                                   Leprecan-like 1                              NM_018192.3         −2.9
  CTSH                                        Cathepsin H                                NM_004390.3         −2.9
  KHDRBS3                             RNA-binding protein T-Star                         NM_006558.1         −3.0
  CDH11                            Cadherin 11, type 2, OB-cadherin                      NM_001797.2         −3.1
  DDIT4L                        DNA-damage-inducible transcript 4-like                   NM_145244.3         −3.2
  GAPDHL6                                       GAPDHL7                                 XM_001726954.1       −3.2
  NR5A2                     Nuclear receptor subfamily 5, group A, member 2              NM_003822.3         −3.3
  ABCA3                      ATP-binding cassette, sub-family A, member 3                NM_001089.2         −3.3
  MARCH2                           Membrane-associated ring finger 2                    NM_001005416.1       −3.3
  CDKN2A                         Cyclin-dependent kinase inhibitor 2A                    NM_000077.4         −3.3
  MGP                                     Matrix Gla protein                             NM_000900.3         −3.3
  ALDH1A2                     Aldehyde dehydrogenase 1 family, member A2                 NM_170697.2         −3.5
  HOXB7                                       Homeobox B7                                NM_004502.3         −3.5
  EMCN                                         Endomucin                                 NM_016242.3         −3.5
  ANGPT2                                    Angiopoietin 2                               NM_001147.2         −3.5
  GIMAP5                             GTPase, IMAP family member 5                        NM_018384.4         −3.6
  NDN                                       Necdin homolog                               NM_002487.2         −3.8
  TACSTD2                     Tumor associate calcuim signal transducer 2                NM_002353.2         −3.8
  KRT19                                       Keratin 19                                 NM_002276.4         −3.8
  FAM174B                    Family with sequence similarity 174, member B               NM_207446.2         −3.9
  CECR1                     Cat eye syndrome chromosome region, candidate 1              NM_177405.1         −4.2
  GPR116                            G protein-coupled receptor 116                       NM_015234.4         −4.3
  TNFRSF6B                Tumor necrosis factor superfamily, member 6b, decoy            NM_032945.2         −4.3
  PIEZO2                  Piezo-type mechanosensitive ion channel component 2            NM_022068.2         −4.4
  UCHL1                         Ubiquitin carboxyl-terminal esterase L1                  NM_004181.4         −4.9
  KBTBD11                      Kelch repeat and BTB domain containing 11                 NM_014867.2         −5.3
  LOC375295                                    LOC375296                                 XM_374020.4         −5.5
  HSD17B2                           Hydroxysteroid dehydrogenase 2                       NM_002153.2         −8.4
  LYVE1                   Lymphatic vessel endothelial hyaluronan receptor 1             NM_006691.3         −8.8
  PDPN                                        Podoplanin                                NM_001006625.1      −15.8
  GYPC                                       Glycophorin C                               NM_016815.3        −22.6
  MMP1                                 Matrix metallopeptidase 1                         NM_002421.3        −25.8
  FABP4                         Fatty acid binding protein 4, adipocyte                  NM_001442.2        −28.1
  CLDN11                                      Claudin 11                                 NM_005602.5        −36.9

We confirmed a small subset of these gene expression changes utilizing qPCR, revealing equivocal trends in gene expression between the microarray and qPCR data for *ANGPT2, ANTXR1, SMARCE1, RGS5, CTAG2, LTBP2, CLDN11,* and *KISS1* (Table [2](#T2){ref-type="table"}). Each of these genes has been firmly established to play critical roles in regulating angiogenesis and/or tumor progression \[[@B10]-[@B17]\]. Missense mutations in *ANTXR1* have been reported in several infantile hemangiomas and contribute to the constitutive VEGFR2 signaling associated with these tumors \[[@B18]\]. Mutations and signaling aberrations in Tie2, the cognate receptor for ANGPT2, play central roles in the development of various vascular disorders \[[@B19],[@B20]\]. ANGPT2 has previously been shown to be down-regulated in response to serum in HEMECs \[[@B19]\]. Interestingly, ANGPT2 expression is higher in HEMECs compared to normal placental endothelial cells and is increased in proliferative infantile hemangioma tumors relative to involuting ones \[[@B5]\]. Virtually undetectable in normal vasculature, *RGS5* is greatly upregulated in the vasculature of solid tumors and may have the potential to serve as a tumor biomarker \[[@B12]\]. The downregulation of the metastasis suppressor *KISS1* that we observed in HEMECs may partially explain the locally aggressive properties of infantile hemangiomas, as this gene encodes an angiogenic suppressor \[[@B16],[@B21]\]. Moreover, the expression of *KISS1* is markedly reduced in aggressive metastatic melanomas and breast cancers, and this loss of expression contributes to the metastatic phenotype of these cells \[[@B17],[@B22]\]. It is intriguing that such genes (particularly the cancer-specific genes) are aberrantly expressed in HEMECs, and undoubtedly their deregulation could potentiate aberrant vascular tumor states. As it has been proposed that infantile hemangiomas may be derived from motile placental-derived chorangioma cells \[[@B2]\], future genomics analysis should compare the transcriptomes of each tumor type to identify if aberrant expression of tumor-related genes is shared between the tissues.

###### 

qPCR confirmation of a subset of gene expression changes in HEMECs compared to HDMVECs

  **Gene**   **Expression Δ**
  ---------- ------------------
  RGS5       92.4 ± 11.2
  CTAG2      39.9 ± 4.8
  SMARCE1    4.4 ± 1.4
  LTBP2      3.3 ± 0.5
  ANGPT2     −2.1 ± 0.3
  KISS1      −2.5 ± 0.4
  ANTXR1     −2.8 ± 0.4
  CLDN11     −10.0 ± 0.9

p≤0.05 for all values.

Overexpression of the CTAG2 cancer/testis antigen in a panel of infantile hemangioma tumors
-------------------------------------------------------------------------------------------

In our microarray analysis, the cancer/testis antigen CTAG2 displayed the highest upregulation of mRNA expression in HEMECs compared to the HDMECs. This gene, whose function is completely unknown, has been shown to be significantly increased in several metastatic cancers, and is actively being researched as a target of immune therapy for aggressive cancers \[[@B23]-[@B29]\]. If CTAG2 is preferentially upregulated in infantile hemangiomas, it is possible that treatment of disfiguring or life threatening infantile hemangioma tumors could employ immune therapy against this antigen. Furthermore, CTAG2 is reported to be a target for antigen-specific T-cells in patients with various metastatic tumors \[[@B29],[@B30]\]. A recent study has shown that nearly half of the patients with spontaneous CTAG2-specific CD4(+) T cell responses had circulating CTAG2-specific antibodies that recognized epitopes located in the C-terminal portion of CTAG2 \[[@B30]\]. As involution of infantile hemangiomas is believed to be due in part to an immune mediated attack on the tumor itself \[[@B4]\], it is possible that T-cell targeting of the overexpressed CTAG2 protein could contribute to this process. We confirmed our microarray data at the protein level by performing immunohistochemistry on a panel of 16 paraffin embedded infantile hemangioma tumors representing both the proliferating and involuting stages of the disease and 4 normal neonatal dermal tissues. A limited amount of CTAG2 expression was observed in the normal dermal tissues (a few nerve cells and bundles present staining, whereas the fibroblasts and collagen fibers are negative), and despite this gene being coined a "cancer/testis specific antigen", analysis of publically available microarray datasets suggests this gene is expressed at a low level across a large number of tissues (<http://www.biogps.org>) and it has been reported in the literature to be expressed in the placenta and ovary \[[@B31]\]. In proliferating tumors (composed of densely proliferating endothelial cells), we observed intense CTAG2 staining in the endothelial cells for all sections analyzed (Figure [2](#F2){ref-type="fig"}). In contrast, involuting tumors (marked by substantial adipocyte deposits---a characteristic of the later stages in the development of this tumor \[[@B32]\]) exhibited significantly reduced levels of CTAG2 staining. As Calicchio et al. did not detect significant differences in CTAG2 expression between microdissected endothelial cells from proliferating and involuting infantile hemangiomas and the staining intensity of individual blood vessels appears relatively constant between proliferating and involuting hemangiomas, we suspect that the reduced CTAG2 staining in involuting tumors is most likely due to reductions in tumor vascular density but not changes in gene transcription.

![**Detection of CTAG2 protein levels in infantile hemangioma tissues.** Proliferating and involuting infantile hemangioma tissues as well as normal neonatal foreskin tissues were cut from paraffin blocks, incubated with antibodies against CTAG2, and detected using alkaline phosphatase staining (*red*). Immunohistochemistry (*IHC*) controls included incubations without CTAG2 antibody (*negative control*) and with CTAG2 antibody (*positive control*) in thin sections from metastatic breast cancer. All images were obtained at 100X total magnification.](2045-824X-5-6-2){#F2}

Conclusion
==========

Our data indicate that global transcriptional expression patterns are markedly unique between pure cultures of HDMVECs and HEMECs with major alterations in cell cycle, adhesion, and arachidonic acid metabolism genes. Though considered benign, HEMECs showed surprising aberrant regulation in the expression of several genes involved in tumor progression. Our finding that CTAG2 is highly expressed in infantile hemangiomas may lead to the development of immune-mediated therapies against infantile hemangiomas.
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